Late Stent Strut Apposition and Coverage After Drug-Eluting Stent Implantation by OCT in Patients With AMI

Inclusion Criteria:

• Acute myocardial infarction including ST-segment elevation myocardial infarction (STEMI) or non ST-segment elevation myocardial infarction (NSTEMI) treated with PCI
• Patient ≥ 18 years of age
• Patient judged suitable to receive anti-platelet drugs of ASA and ticagrelor for at least 12 months after the procedure
• The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic, OCT follow up and provides informed consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.
• culprit lesion

Exclusion Criteria:

• The patient has a known hypersensitivity or contraindication to any of the following medications: heparin, abciximab, aspirin, ticagrelor, everolimus, zotarolimus, polymer, platinum chromium, cobalt chromium, contrast media
• Female of childbearing potential unless a pregnancy test is negative or who possibly plan to become pregnant any time after enrollment
• Cardiogenic shock
• Patient with left ventricular ejection fraction <30%
• Patient with left main disease
• Patient with In-stent restenosis (ISR) at target vessel (either bare metal stent or DES, non-target vessel ISR is permitted)
• Patient with impaired renal function (creatinine >2.0mg/dL)
• Patient with inadequate OCT images quality due to severe calcification, vessel tortuosity and artifacts
• bifucation lesion needs complex procedure with insert two or more Drug eluting stents.
• lesion length >30mm